L01EM01 • idelalisib • Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Phosphatidylinositol-3-kinase (PI3K) inhibitors
Idelalisib is a medication used to treat certain types of blood cancer, such as chronic lymphocytic leukemia (CLL) and follicular lymphoma. It is a PI3K-delta kinase inhibitor, which plays a key role in the survival and proliferation of cancer cells.
The medication is taken orally, usually twice daily, as directed by a doctor.
Side effects may include diarrhea, nausea, fever, fatigue, or infections. In rare cases, severe adverse effects such as hepatotoxicity or pneumonitis may occur.
Patients should be closely monitored during treatment and inform their doctor about any other medications they are taking. Pregnant or breastfeeding women should consult a specialist before use.
Substance: idelalisib
Date of last drug list: 16-08-2017
Commercial code: W63550001
Concentration: 150mg
Pharmaceutical form: tablets
Quantity: 60
Product type: original
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).